(Sharecast News) - Shares in Hikma Pharmaceuticals surged on Thursday as investors welcomed new medium-term guidance from the company.
Alongside a sell-side analysts and investors even at its manufacturing and R&D facility in Columbus, Ohio, the pharmaceuticals group said that for group revenue, it expects a three-year compound annual growth rate of 6% to 8% between 2024 and 2027.

For operating profit, it expects a three-year compound annual growth rate of 7% to 9%.

In addition, Hikma said introduced a five-year target for group revenue to reach $5bn by 2030.

At 1235 BST, the shares were up 8.1% at 2,098p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE